Litcius/Paper detail

A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes

Roy W. Beck, Ryan J. Bailey, Halis Kaan Aktürk, Shafaq Rizvi, Yogish C. Kudva, Thomas Blevins, Mei Mei Church, Anastasios Manessis, Peter Calhoun, Katrina J. Ruedy, Irl B. Hirsch, for the INHALE-3 Study Group

2025Diabetes Technology & Therapeutics10 citationsDOI

Abstract

In adults with T1D, glycemic outcomes were comparable or slightly better with TI-degludec after switching from AID or MDI. TI should be considered as an option for individuals who want an alternative to using an insulin pump or MDI for insulin delivery.

Topics & Concepts

MedicineInsulin degludecInsulinDiabetes mellitusType 1 diabetesType 2 diabetesInternal medicineEndocrinologyInsulin glargineDiabetes Management and ResearchPancreatic function and diabetesDiabetes and associated disorders
A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes | Litcius